Chronic PeriodontitisPhase 2/3NCT02538224
Efficacy of Subgingivally Delivered Doxycycline Plus Ketoprofen Gel as an Adjunct to Non-surgical Periodontal Treatment
A Phase 2/3 study testing 2.5%ketoprofen gel + 3 % doxycycline and :2.5%ketoprofen gel in people with Chronic Periodontitis, run by Islamic Azad University, Sanandaj.
Trial summary
Objectives: The aim of the present clinical study was to evaluate the efficacy of doxycyline 3% plus ketoprofen 2.5% as an adjunct to scaling and root planing in the treatment of chronic periodontitis(early-modearte). Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Chronic Periodontitis
- What is being tested?
- 2.5%ketoprofen gel + 3 % doxycycline and :2.5%ketoprofen gel
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 20 participants
- Where
- No sites listed yet
- Study dates
- Jul 2013to Jun 2014
- Phase
- Phase 2/3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- adult patients,
- older than 18 years old,
- systemically healthy, and
- having at least 20 teeth.
Who cannot join
- patients with cavitated caries,
- no periodontal pockets larger than 4 mm,
- orthodontic appliances or removable prostheses,
- allergies to cetylpyridinium or CHX,
- use of antibiotics and anti-inflammatory drugs in the past 3 months that might alter normal gingival health,
- oral prophylaxis outside of study;
Show all 9Show fewer
- use of oral chlorhexidine products or participation in an oral rinse study within 3 months prior to baseline examination,
- pregnancy or lactation,
- smoking.
About this study
Official title: Randomized, Double Blind, Placebo Controlled Clinical Trial of Compare With Doxycycline Plus Ketoprofen Gel in Chronic Periodontitis
Objectives: The aim of the present clinical study was to evaluate the efficacy of doxycyline 3% plus ketoprofen 2.5% as an adjunct to scaling and root planing in the treatment of chronic periodontitis(early-modearte). Material and Methods: 20 systemically healthy, chronic periodontitis patients were included in the study.The Patients were selected on the basis of having chronic periodontitis with periodontal pocket depths of more than 4mm on at least two teeth in mandibular molar area; Periodontal parameters (plaque, bleeding on probing and pocket depth) were recorded at baseline and every 15 days for 3 months. Oral hygiene instructions were given that included brushing twice- daily, (Using the Bass brushing technique for at least 2 minutes ), Randomly divided two groups,Test group: was treated by scaling and root planing Followed by local delivery of doxycycline 3%+ ketoprofen 2.5%, While the control group: was treated by scaling and root planing along with ketoprofen 2.5%; and was administered to the both groups every 15 days for 3 months, repeated. Every 15 days once periodontal parameters were assessed, and at the end of 3 months, evaluated the clinical parameters changes.
Read the detailed description
Source of Data In this 8 month follow up, longitudinal intervention study, a total of 20patients (9 males and 11 females, Age range: 30-50 years) with chronic periodontitis were selected from the outpatient section of the Department of Periodontics, Islamic Azad University Dental School of Tehran /Iran. The study met the criteria of the Helsinki Declaration of1975, revised in 2008. The survey plan was reviewed and sanctioned, approved by the ethics commission of the Institutional Ethical Committee and Review Board of the Deputy of Research, School of Dentistry. All subjects received oral and written explanation of the intent of the survey and signed an informed consent after receiving detailed information about the purpose, the benefits, and the possible risks associated with the trial. The study was conducted from October 2012 to November 2013. The study was registered at the Iranian registry of clinical trials (IRCT), registration code: IRCT2014050717587N2.
Selection Criteria Patients meeting all of the following criteria were included in the study: aged between 30 and 45 years; 20 natural teeth present; clinical and radiographic signs of moderate (clinical attachment level of 2 to 3mm); probing depth (PD) of >4 mm; no periodontal treatment the previous 6 months; and willingness to comply with the study protocol.
Patients were excluded from the study if they met one or more of the following criteria: 1) existing systemic disease that may influence the severity or progression of periodontitis; taking medications that may influence the periodontium (e.g., non-steroidal anti-inflammatory drugs) or other medicines (antibiotic) within the 6 months preceding the beginning of the study; concurrent or planned orthodontic treatments; planned extensive dental restorations; patients with cavitated caries; pregnancy or lactation; mouth rinses during the entire period of the study; hypersensitive to doxycycline or ketoprofen; smoking.
Grouping Criteria Patients received scaling and root planing on first visit in accordance with the one stage full-mouth debridement protocol + polishing; the therapeutic endpoint was defined as a clean root surface void of visible or clinically detectable remnants of biofilm or calculus. After 2 weeks (debridement), was applied into all periodontal pockets with PD of ≥4 mm using a syringe with a blunt canula. The canula was inserted to the base of the periodontal pocket and gel was applied 0/5 ml on each side of the mandible. After patient enrollment by an examiner; using blocked randomization with a block size of 4 and an allocation ratio of 1:1 Block randomization was chosen to prevent too much variability in the number of patients randomized and ensure a reasonably steady flow of patients to each treatment group, Allocation cover was ensured by using container and labeling that did not reveal the content of the trial drug packages who was blind to the therapist and the clinical examination. Patients were randomly assigned to either the A or B group, while mandibular arches are each divided into two parts (left and right sections) with 100 sites in both groups.
In the A group, was treated by scaling and root planing (SRP) followed by local delivery of doxycycline 3%+ ketoprofen 2.5%, while the B group was treated by scaling and root planing along with ketoprofen 2.5%; and was administered to the both groups every 15 days for 3 months. After treatment, patients were given thorough oral hygiene instructions, the trial gel for local application contained ketoprofen gel (2.5% Sanofi Pharmaceutical plant construction in France) + 3 % doxycycline (Kharazmi Pharmaceutical manufacture in Iran) in the group (A), another group (B) ketoprofen 2.5%gel was used. After treatment, patients were given thorough oral hygiene instructions and were asked to use dentifrice sodium fluorides (Crest cavity protection) and to finish from using any mouthwashes during the course of the study. The subjects were given careful instructions in self-performed plaque-control measures: twice-daily tooth brushing using the Bass brushing technique with a soft toothbrush and a regular fluoride containing toothpaste and once-daily Interdental cleaning using dental floss. Clinical parameters, including Plaque Index (PI) (18), sulcus bleeding index (19). Probing depth (PD) and clinical attachment level (CAL) were recorded at baseline (before the SRP) and at 0, 15,30,45,60 days and 3 months. William's periodontal probe was used to standardize the measurement of clinical parameters. All pre- and post-treatment clinical parameters were recorded by an examiner who was masked to the type of treatment received by the patients while another clinician provided treatment for both groups. All pre- and post-treatment clinical parameters were recorded by an examiner who was masked to the type of treatment received by the patients while another clinician provided treatment for both groups.
- Conditions
- Chronic Periodontitis
- Being tested
- 2.5%ketoprofen gel + 3 % doxycycline, :2.5%ketoprofen gel
- Keywords
- Periodontitis, doxycycline/ketoprofen topical gel therapeutic
- Medical subject headings
- Chronic Periodontitis, Periodontitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
2.5%ketoprofen gel + 3 % doxycyclineDrug
Also called Experimental
GroupA:(0.05cc, mixed gel) be put into the periodontal pocket using an insulin syringe.
Intervention category Treatment: drugs
:2.5%ketoprofen gelDrug
Also called control
GroupB:2.5%ketoprofen gel which be inserted into the periodontal pocket using an insulin syringe .
| Study group | Role | What they receive |
|---|---|---|
| experimental(case): group A | Active comparator | Group A: 2.5%ketoprofen gel + 3 % doxycycline gel which(0.05cc,mixed gel) be put into the periodontal pocket using an insulin syringe;For every 15 days within 3 months . Receives: Drug: 2.5%ketoprofen gel + 3 % doxycycline; Drug: :2.5%ketoprofen gel |
| control: group B | Sham comparator | Group B: 2.5%ketoprofen gel which (0.05cc,gel)be put into the periodontal pocket using an insulin syringe;For every 15 days within 3 months . Receives: Drug: :2.5%ketoprofen gel |
What is being measured
The primary outcome is the main question the study is designed to answer.
Reduction of pocket depth
Measured: 15 days
Secondary outcomes (1)
Reduction of bleeding on probing
Measured: 15 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Sep 2015 (estimated)
- Study startJul 2013
- Primary completionFeb 2014
- Study completionJun 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic PeriodontitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- Islamic Azad University, Sanandaj
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Amirhossein Farahmand, Islamic Azad University, Sanandaj
- Investigators
- amirhossein farahmand, assoc prof, Principal investigator, azad tehran
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02538224
- Sponsor's protocol ID
- azadtehran
- Status last verified
- Jun 2016
- First submitted
- 20 Aug 2015
- Last updated
- 6 Jun 2016
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Jun 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized, Double Blind, Placebo Controlled Clinical Trial of Compare With Doxycycline Plus Ketoprofen Gel in Chronic Periodontitis
- ClinicalTrials.gov ID
- NCT02538224
- Acronym / sponsor ID
- azadtehran
- Conditions
- Chronic Periodontitis
- Keywords
- Periodontitis, doxycycline/ketoprofen topical gel therapeutic
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Islamic Azad University, SanandajUniversity, hospital or other
- Study start
- Jul 2013
- Primary completion
- Feb 2014 (actual)
- Study completion
- Jun 2014 (actual)
- First posted
- 2 Sep 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Objectives: The aim of the present clinical study was to evaluate the efficacy of doxycyline 3% plus ketoprofen 2.5% as an adjunct to scaling and root planing in the treatment of chronic periodontitis(early-modearte). Material and Methods: 20 systemically healthy, chronic periodontitis patients were included in the study.The Patients were selected on the basis of having chronic periodontitis with periodontal pocket depths of more than 4mm on at least two teeth in mandibular molar area; Periodontal parameters (plaque, bleeding on probing and pocket depth) were recorded at baseline and every 15 days for 3 months. Oral hygiene instructions were given that included brushing twice- daily, (Using the Bass brushing technique for at least 2 minutes ), Randomly divided two groups,Test group: was treated by scaling and root planing Followed by local delivery of doxycycline 3%+ ketoprofen 2.5%, While the control group: was treated by scaling and root planing along with ketoprofen 2.5%; and was administered to the both groups every 15 days for 3 months, repeated. Every 15 days once periodontal parameters were assessed, and at the end of 3 months, evaluated the clinical parameters changes.
Detailed description
Source of Data In this 8 month follow up, longitudinal intervention study, a total of 20patients (9 males and 11 females, Age range: 30-50 years) with chronic periodontitis were selected from the outpatient section of the Department of Periodontics, Islamic Azad University Dental School of Tehran /Iran. The study met the criteria of the Helsinki Declaration of1975, revised in 2008. The survey plan was reviewed and sanctioned, approved by the ethics commission of the Institutional Ethical Committee and Review Board of the Deputy of Research, School of Dentistry. All subjects received oral and written explanation of the intent of the survey and signed an informed consent after receiving detailed information about the purpose, the benefits, and the possible risks associated with the trial. The study was conducted from October 2012 to November 2013. The study was registered at the Iranian registry of clinical trials (IRCT), registration code: IRCT2014050717587N2.
Selection Criteria Patients meeting all of the following criteria were included in the study: aged between 30 and 45 years; 20 natural teeth present; clinical and radiographic signs of moderate (clinical attachment level of 2 to 3mm); probing depth (PD) of >4 mm; no periodontal treatment the previous 6 months; and willingness to comply with the study protocol.
Patients were excluded from the study if they met one or more of the following criteria: 1) existing systemic disease that may influence the severity or progression of periodontitis; taking medications that may influence the periodontium (e.g., non-steroidal anti-inflammatory drugs) or other medicines (antibiotic) within the 6 months preceding the beginning of the study; concurrent or planned orthodontic treatments; planned extensive dental restorations; patients with cavitated caries; pregnancy or lactation; mouth rinses during the entire period of the study; hypersensitive to doxycycline or ketoprofen; smoking.
Grouping Criteria Patients received scaling and root planing on first visit in accordance with the one stage full-mouth debridement protocol + polishing; the therapeutic endpoint was defined as a clean root surface void of visible or clinically detectable remnants of biofilm or calculus. After 2 weeks (debridement), was applied into all periodontal pockets with PD of ≥4 mm using a syringe with a blunt canula. The canula was inserted to the base of the periodontal pocket and gel was applied 0/5 ml on each side of the mandible. After patient enrollment by an examiner; using blocked randomization with a block size of 4 and an allocation ratio of 1:1 Block randomization was chosen to prevent too much variability in the number of patients randomized and ensure a reasonably steady flow of patients to each treatment group, Allocation cover was ensured by using container and labeling that did not reveal the content of the trial drug packages who was blind to the therapist and the clinical examination. Patients were randomly assigned to either the A or B group, while mandibular arches are each divided into two parts (left and right sections) with 100 sites in both groups.
In the A group, was treated by scaling and root planing (SRP) followed by local delivery of doxycycline 3%+ ketoprofen 2.5%, while the B group was treated by scaling and root planing along with ketoprofen 2.5%; and was administered to the both groups every 15 days for 3 months. After treatment, patients were given thorough oral hygiene instructions, the trial gel for local application contained ketoprofen gel (2.5% Sanofi Pharmaceutical plant construction in France) + 3 % doxycycline (Kharazmi Pharmaceutical manufacture in Iran) in the group (A), another group (B) ketoprofen 2.5%gel was used. After treatment, patients were given thorough oral hygiene instructions and were asked to use dentifrice sodium fluorides (Crest cavity protection) and to finish from using any mouthwashes during the course of the study. The subjects were given careful instructions in self-performed plaque-control measures: twice-daily tooth brushing using the Bass brushing technique with a soft toothbrush and a regular fluoride containing toothpaste and once-daily Interdental cleaning using dental floss. Clinical parameters, including Plaque Index (PI) (18), sulcus bleeding index (19). Probing depth (PD) and clinical attachment level (CAL) were recorded at baseline (before the SRP) and at 0, 15,30,45,60 days and 3 months. William's periodontal probe was used to standardize the measurement of clinical parameters. All pre- and post-treatment clinical parameters were recorded by an examiner who was masked to the type of treatment received by the patients while another clinician provided treatment for both groups. All pre- and post-treatment clinical parameters were recorded by an examiner who was masked to the type of treatment received by the patients while another clinician provided treatment for both groups.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| experimental(case): group A | Active comparator | Drug: 2.5%ketoprofen gel + 3 % doxycycline, Drug: :2.5%ketoprofen gelGroup A: 2.5%ketoprofen gel + 3 % doxycycline gel which(0.05cc,mixed gel) be put into the periodontal pocket using an insulin syringe;For every 15 days within 3 months . |
| control: group B | Sham comparator | Drug: :2.5%ketoprofen gelGroup B: 2.5%ketoprofen gel which (0.05cc,gel)be put into the periodontal pocket using an insulin syringe;For every 15 days within 3 months . |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (4 listed)
- adult patients,
- older than 18 years old,
- systemically healthy, and
- having at least 20 teeth.
Key exclusion criteria (9 listed)
- patients with cavitated caries,
- no periodontal pockets larger than 4 mm,
- orthodontic appliances or removable prostheses,
- allergies to cetylpyridinium or CHX,
- use of antibiotics and anti-inflammatory drugs in the past 3 months that might alter normal gingival health,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 2.5%ketoprofen gel + 3 % doxycyclineAlso: ExperimentalGroupA:(0.05cc, mixed gel) be put into the periodontal pocket using an insulin syringe. Intervention category Treatment: drugs | Drug | experimental(case): group A |
| :2.5%ketoprofen gelAlso: controlGroupB:2.5%ketoprofen gel which be inserted into the periodontal pocket using an insulin syringe . | Drug | control: group B, experimental(case): group A |
Primary outcome
Reduction of pocket depth
Time frame: 15 days
1 secondary outcome
Reduction of bleeding on probing
Time frame: 15 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jun 2016.
- Individual participant dataSharing planned: No
Related trials for Chronic Periodontitis
Not yet recruiting
Clinical and Inflammatory Outcomes of Regenerative Endodontic Treatment Using Injectable Platelet-Rich Fibrin in Mature Necrotic Teeth With Chronic Apical Periodontitis.
Chronic Apical Periodontitis, Pulp Necrosis
Recruiting
Effect of Cyperus Articulatus on Bacterial Reduction and Postoperative Pain
Chronic Apical Periodontitis
RecruitingObservational study
Prevalence and Associated Factors of High BMI and Periodontitis in Thai Adults Aged Under 60 Years
Diabete Mellitus, Dyslipidaemia
RecruitingObservational study
Evaluation of Masticatory Performance in Patients With Periodontitis
Periodontitis, Adult, Periodontitis
Recruiting
Postoperative Pain and Success of Single-Visit Root Canal Treatment Using Different Root Canal Sealers in Asymptomatic Teeth
Single-visit, Periapical Periodontitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
amirhossein farahmand, assoc prof principal investigator
azad tehran
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing 2.5%ketoprofen gel + 3 % doxycycline and :2.5%ketoprofen gel in people with Chronic Periodontitis, run by Islamic Azad University, Sanandaj.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Jun 2016. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Reduction of pocket depth (time frame: 15 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jun 2016.